Infliximab or Adalimumab, Vs Abatacept, in Patients With RA
Infliximab or Adalimumab, Vs Abatacept, in Patients With RA
The core question of comparative effectiveness research is which treatment works best, for whom and under what circumstances. Currently it is not possible to predict, on an individual basis, which patients will respond to a particular therapy. In the absence of reliable biomarkers on which to base individual treatment decisions, current biological therapies all have relatively good efficacy in RA and target similar populations of patients. The ATTEST–AMPLE network randomized trial strongly suggests that abatacept in combination with MTX is comparable to other biologic DMARDs (applied in the right dose) for the reduction of disease activity of RA in patients with active disease, despite previous treatment with MTX. At present, the focus of clinicians may have to rest solely on clinical disease activity assessment and on rapidly targeting remission or low disease activity.
Conclusion & Future Perspective
The core question of comparative effectiveness research is which treatment works best, for whom and under what circumstances. Currently it is not possible to predict, on an individual basis, which patients will respond to a particular therapy. In the absence of reliable biomarkers on which to base individual treatment decisions, current biological therapies all have relatively good efficacy in RA and target similar populations of patients. The ATTEST–AMPLE network randomized trial strongly suggests that abatacept in combination with MTX is comparable to other biologic DMARDs (applied in the right dose) for the reduction of disease activity of RA in patients with active disease, despite previous treatment with MTX. At present, the focus of clinicians may have to rest solely on clinical disease activity assessment and on rapidly targeting remission or low disease activity.
Source...